![Sophia Park](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Sophia Park
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Impact Biomedicines, Inc.
![]() Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA.
1
| Subsidiary | Medical Specialties | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Sophia Park
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Levicept Ltd.
![]() Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Chairman | |
UltraHuman Ltd.
![]() UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Morphogen-IX Ltd.
![]() Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Stealthyx Therapeutics Ltd.
![]() Stealthyx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Stealthyx Therapeutics Ltd. operates drug delivery system technology. The company was founded by Yuti Chernajovsky and Eileen Janis Anderson in 2002 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Capella Bioscience Ltd.
![]() Capella Bioscience Ltd. Pharmaceuticals: MajorHealth Technology Capella Bioscience Ltd. develops medicines based on monoclonal antibodies to the next generation therapeutic targets in oncology and autoimmune disease. The company was founded by Steve Holmes in 2014 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
ApcinteX Ltd.
![]() ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Inhibitaxin Ltd.
![]() Inhibitaxin Ltd. BiotechnologyHealth Technology Inhibitaxin Ltd. engages in research and development on biotechnology. The company was founded by Simon Lempriere Westbrook and Kevin S. Johnson in 2013 and is headquartered in Kent, the United Kingodm. | Biotechnology | Founder | |
Medicxi Ventures (Jersey) Ltd.
![]() Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Founder | |
ACUTUS MEDICAL, INC. | Medical Specialties | Director/Board Member | |
The University of Edinburgh | College/University | Undergraduate Degree | |
MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member | |
Index Ventures (UK) LLP | Investment Managers | Private Equity Investor | |
MedImmune Ltd.
![]() MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Corporate Officer/Principal | |
University of Melbourne
![]() University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | College/University | Corporate Officer/Principal | |
University of Cambridge | College/University | Doctorate Degree | |
Rebalance (Cambridge) Ltd.
![]() Rebalance (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Rebalance (Cambridge) Ltd. provides research and experimental development on biotechnology. The company was founded on December 6, 2016 and is headquartered in Hatfield, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member |
Statistik
International
Vereinigtes Königreich | 15 |
Vereinigte Staaten | 5 |
Niederlande | 2 |
Schweiz | 2 |
Australien | 2 |
Sektoral
Health Technology | 13 |
Commercial Services | 5 |
Consumer Services | 4 |
Finance | 3 |
Operativ
Director/Board Member | 13 |
Corporate Officer/Principal | 3 |
Chairman | 2 |
Founder | 2 |
Private Equity Investor | 2 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Kevin Johnson | 22 |
- Börse
- Insiders
- Sophia Park
- Unternehmensverbindungen